Modify Clinical Study Protocol: CDSCO Panel Tells Roche On Multiple Sclerosis Drug Ocrelizumab Dr. Divya Colin11 Feb 2024 6:00 PM ISTNew Delhi: In response to the proposal presented by drug major Roche to conduct the Phase IV clinical trial for the drug product Ocrelizumab 300 mg...
CDSCO Panel Approves Novartis Protocol Amendment Proposal For Multiple Sclerosis Drug Ofatumumab Dr. Divya Colin11 Feb 2024 6:00 PM ISTNew Delhi: The Subject Expert Committee (SEC) functional under the Central Drug Standard Control Organisation (CDSCO) has approved the drug major...
Submit Modified Informed Consent Form with details: CDSCO Panel Tells Sanofi om Multiple Sclerosis Drug Tolebrutinib Dr. Divya Colin21 Jan 2024 6:00 PM ISTNew Delhi: Reviewing the Phase III clinical study protocol of Tolebrutinib presented by the drug major Sanofi, the Subject Expert Committee (SEC)...
Health Bulletin 29/07/2023 Roshni Dhar29 July 2023 5:17 PM ISTHere are the Top health stories for the day:WHO approves important health choices for multiple sclerosis medicinesWorld Health Organization (WHO)...
Novartis bid to revive multiple sclerosis drug Gilenya patent rebuffed by US Supreme Court Ruchika Sharma18 April 2023 12:30 PM ISTThe USFDA in 2010 approved Gilenya to treat relapsing forms of multiple sclerosis.
Roche flags 2023 earnings decline on slump in COVID products Ruchika Sharma3 Feb 2023 11:21 AM ISTAnalysts have said that market confidence in Roche's drug development abilities, previously among the highest in the industry, has taken a blow from...
US Supreme Court turns down Novartis bid to block launch of multiple sclerosis drug Gilenya generics Ruchika Sharma15 Oct 2022 1:30 PM ISTNovartis settled with some of the drugmakers it had sued, allowing for some Gilenya generics before a key patent's 2027 expiration.
Novartis to take US drug patent case to Supreme Court Ruchika Sharma22 Sept 2022 3:46 PM ISTZurich: Novartis AG plans to ask the U.S. Supreme court to uphold the validity of a patent it holds on the dosing regimen for multiple sclerosis drug...
Whistleblower case alleging kickback for promotion of Novartis MS drug Gilenya dismissed Ruchika Sharma14 Sept 2022 2:30 PM ISTNovartis moved to dismiss, arguing that Camburn still had not offered enough detail to support his claim of a fraudulent scheme.
Setback to Novartis: US Court declares multiple sclerosis drug Gilenya patent invalid Ruchika Sharma22 Jun 2022 12:30 PM ISTNovartis also said it believes HEC and others cannot launch generic versions of Gilenya during the ongoing appeal process.
